Supplementary Figure S5 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Year: 2024
Type: supplementary-materials
Abstract: Elevated circulating free fatty acids (FFA) at days 57 and 85 in PR patients. Log2-fold changes in baseline normalized FFA in patients enrolled in Part 2. Samples were collected prior to TPST-1120 dose administration on day 1 of each 28-day cycle. Blue symbols: PD/SD patients; Red symbols: PR patients.
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4394914949